{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:21:02Z","timestamp":1789791662948,"version":"4.0.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Kidney transplant recipients with severe acute respiratory syndrome-coronavirus-2 infection have an increased risk of severe disease and mortality. Nirmaltrevir\/ritonavir (Paxlovid) is an effective oral disease-modifying therapy that has been shown to reduce risk of progression to severe disease in high-risk, nonhospitalized adults. However, owing to the potential for serious drug\u2013drug interactions owing to ritonavir-induced inhibition of the CYP3A enzyme, this drug is not suitable option for transplant recipients with mild-moderate severe acute respiratory syndrome-coronavirus-2 infection.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 57-year-old Caucasian man presented to the emergency department with 48\u00a0hours of nausea, vomiting, headaches, and lethargy. At 5 days earlier, he was diagnosed with a mild severe acute respiratory syndrome-coronavirus-2 infection by his general practitioner, who commenced treatment with Paxlovid at 300\u00a0mg\/100\u00a0mg twice daily. Past medical history included kidney transplantation in 2018 for end-stage kidney secondary to hypertensive nephrosclerosis, managed with prednisone, tacrolimus, and mycophenolate. Vaccination status was up-to-date and prophylactic tixagevimab\/cilgavimab (Evusheld) had been given\u2009&gt;\u20096\u00a0months prior owing to lack of seroconversion. Examination showed a blood pressure of 176\/94 mmHg and normal respiratory parameters. Investigations demonstrated a serum creatinine of 213\u00a0\u00b5mol\/L (baseline 130\u00a0\u00b5mol\/L) and tacrolimus trough level of 118\u00a0\u00b5g\/L (baseline 6.9\u20138.7\u00a0\u00b5g\/L). Treatment included intravenous rehydration, Evusheld and tacrolimus were withheld for 7\u00a0days, with recommencement guided by regular therapeutic drug monitoring.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This acute kidney injury was attributed to tacrolimus toxicity resulting from a drug\u2013drug interaction with Paxlovid. While transplant recipients have an increased risk of severe disease, current Australian guidelines recommend against Paxlovid use in adults taking medications that are heavily dependent on CYP3A4 for clearance, including calcineurin and mammalian target of rapamycin inhibitors.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-024-04990-6","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T05:53:04Z","timestamp":1734673984000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Acute kidney injury and tacrolimus toxicity in a kidney transplant recipient treated with nirmaltrevir\/ritonavir: a case report"],"prefix":"10.1186","volume":"18","author":[{"given":"Jack","family":"Rycen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Jefferis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mudge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"issue":"11","key":"4990_CR1","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1093\/ndt\/gfab200","volume":"36","author":"E Goffin","year":"2021","unstructured":"Goffin E, Candellier A, Vart P, Noordzij M, Arnol M, Covic A, Lentini P, Malik S, Reichert LJ, Sever MS, et\u00a0al. COVID-19-related mortality in kidney transplant and haemodialysis patients: a comparative, prospective registry-based study. Nephrol Dial Transplant. 2021;36(11):2094\u2013105.","journal-title":"Nephrol Dial Transplant"},{"issue":"15","key":"4990_CR2","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","volume":"386","author":"J Hammond","year":"2022","unstructured":"Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Baniecki M, Hendrick VM, Damle B, Sim\u00f3n-Campos A, et\u00a0al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386(15):1397\u2013408.","journal-title":"N Engl J Med"},{"issue":"9","key":"4990_CR3","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1056\/NEJMoa2204919","volume":"387","author":"R Arbel","year":"2022","unstructured":"Arbel R, Wolff Sagy Y, Hoshen M, Battat E, Lavie G, Sergienko R, Friger M, Waxman JG, Dagan N, Balicer R, et\u00a0al. Nirmatrelvir use and severe Covid-19 outcomes during the omicron surge. N Engl J Med. 2022;387(9):790\u20138.","journal-title":"N Engl J Med"},{"issue":"10373","key":"4990_CR4","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0140-6736(22)02597-1","volume":"401","author":"CC Butler","year":"2023","unstructured":"Butler CC, Hobbs FDR, Gbinigie OA, Rahman NM, Hayward G, Richards DB, Dorward J, Lowe DM, Standing JF, Breuer J, et\u00a0al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. The Lancet. 2023;401(10373):281\u201393.","journal-title":"The Lancet"},{"key":"4990_CR5","unstructured":"FDA announces Evusheld is not currently authorized for emergency use in the U.S. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-announces-evusheld-not-currently-authorized-emergency-use-us#update010623."},{"issue":"6","key":"4990_CR6","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2174\/1389200219666180129151948","volume":"19","author":"M Yu","year":"2018","unstructured":"Yu M, Liu M, Zhang W, Ming Y. Pharmacokinetics, pharmacodynamics and pharmacogenetics of tacrolimus in kidney transplantation. Curr Drug Metab. 2018;19(6):513\u201322.","journal-title":"Curr Drug Metab"},{"issue":"12","key":"4990_CR7","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.2165\/00003495-200363120-00006","volume":"63","author":"LJ Scott","year":"2003","unstructured":"Scott LJ, McKeage K, Keam SJ, Plosker GL. Tacrolimus. Drugs. 2003;63(12):1247\u201397.","journal-title":"Drugs"},{"issue":"4","key":"4990_CR8","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2165\/00003088-199835040-00002","volume":"35","author":"A Hsu","year":"1998","unstructured":"Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clin Pharmacokinet. 1998;35(4):275\u201391.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"4990_CR9","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1093\/jac\/dkaa253","volume":"75","author":"F Stader","year":"2020","unstructured":"Stader F, Khoo S, Stoeckle M, Back D, Hirsch HH, Battegay M, Marzolini C. Stopping lopinavir\/ritonavir in COVID-19 patients: duration of the drug interacting effect. J Antimicrob Chemother. 2020;75(10):3084\u20136.","journal-title":"J Antimicrob Chemother"},{"key":"4990_CR10","volume":"2013","author":"AS Jantz","year":"2013","unstructured":"Jantz AS, Patel SJ, Suki WN, Knight RJ, Bhimaraj A, Gaber AO. Treatment of acute tacrolimus toxicity with phenytoin in solid organ transplant recipients. Case Rep Transplant. 2013;2013: 375263.","journal-title":"Case Rep Transplant"},{"issue":"4","key":"4990_CR11","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1053\/j.ajkd.2022.01.001","volume":"79","author":"S Fishbane","year":"2022","unstructured":"Fishbane S, Hirsch JS, Nair V. Special considerations for Paxlovid treatment among transplant recipients with SARS-CoV-2 infection. Am J Kidney Dis. 2022;79(4):480\u20132.","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"4990_CR12","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1111\/ajt.16955","volume":"22","author":"NW Lange","year":"2022","unstructured":"Lange NW, Salerno DM, Jennings DL, Choe J, Hedvat J, Kovac D, Scheffert J, Shertel T, Ratner LE, Brown RS Jr, et\u00a0al. Nirmatrelvir\/ritonavir use: managing clinically significant drug\u2013drug interactions with transplant immunosuppressants. Am J Transplant. 2022;22(7):1925\u20136.","journal-title":"Am J Transplant"},{"issue":"1","key":"4990_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.7326\/M22-2141","volume":"176","author":"S Dryden-Peterson","year":"2022","unstructured":"Dryden-Peterson S, Kim A, Kim AY, Caniglia EC, Lennes IT, Patel R, Gainer L, Dutton L, Donahue E, Gandhi RT, et\u00a0al. Nirmatrelvir plus ritonavir for early COVID-19 in a large U.S. Health System. Ann Intern Med. 2022;176(1):77\u201384.","journal-title":"Ann Intern Med"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-024-04990-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-024-04990-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-024-04990-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T06:03:49Z","timestamp":1734674629000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-024-04990-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4990"],"URL":"https:\/\/doi.org\/10.1186\/s13256-024-04990-6","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,20]]},"assertion":[{"value":"18 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent has been obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"629"}}